Biogen (BIIB) Other Accumulated Expenses (2009 - 2026)

Biogen's Other Accumulated Expenses history runs 18 years deep, the most recent figure standing at $2.5 billion for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 0.64% year-over-year to $2.5 billion; the TTM figure through Mar 2026 stood at $2.5 billion (up 0.64% YoY), while the FY2025 annual figure was $2.8 billion, changed 0.18% from the prior year.
• Other Accumulated Expenses was $2.5 billion for Q1 2026 at Biogen, down from $2.8 billion in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $3.8 billion in Q3 2023 to a low of $2.2 billion in Q1 2022.
• Historically, Other Accumulated Expenses has averaged $2.7 billion across 5 years, with a median of $2.6 billion in 2023.
• The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses gained 29.61% in 2022, then declined 28.22% in 2024.
• A 5-year view of Other Accumulated Expenses shows it stood at $2.5 billion in 2022, then grew by 4.05% to $2.6 billion in 2023, then climbed by 7.02% to $2.8 billion in 2024, then fell by 0.18% to $2.8 billion in 2025, then slipped by 9.13% to $2.5 billion in 2026.
• The last three Other Accumulated Expenses figures came in at $2.5 billion (Q1 2026), $2.8 billion (Q4 2025), and $2.8 billion (Q3 2025), per Business Quant data.